A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of the Oral NLRP3 Inhibitor Dapansutrile in Subjects With Type 2 Diabetes Mellitus
Latest Information Update: 31 Dec 2024
At a glance
- Drugs Dapansutrile (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms Dapan-Dia
- 18 Nov 2024 Trial design presented at the American Heart Association Scientific Sessions 2024
- 16 Jul 2024 New trial record
- 11 Jul 2024 According to an Olatec Therapeutics media release, funding is being provided through the INTERCEPT-T2D initiative by the European Union under the Horizon Europe Programme (GA No 101095433), in collaboration with the Swiss Government and Olatec.